SARS-CoV-2 Humanized Spike Glycoprotein (S) Expression Lentivector, pCDH-CMV-SARS-CoV-2-hS-EF1α-Puro (Plasmid)

SBI is helping scientists around the globe respond to the ongoing COVID-19 pandemic with research tools that get your studies up and running quickly and efficiently. Our SARS-CoV-2 Nucleocapsid (N protein) Expression Lentivector is based on our robust pCDH-CMV-MCS-EF1α-Puro Cloning and Expression Lentivector (Cat.# CD510B-1/VA-1), and delivers SARS-CoV-2 N protein expression from the CMV promoter with a separate EF1α promoter driving the expression of the puromycin resistance gene for selection. Available in both plasmid and pre-packaged lentivirus formats, the SARS-CoV-2 Nucleocapsid (N protein) Expression Lentivector enables a wide range of studies using the systems of your choice.

• Leverage SBI's robust lentivector expression technology to study the SARS-CoV-2 nucleocapsid protein
• Choose ready-to-package plasmid or ready-to-transduce virus
• Additional SARS-CoV-2 expression constructs also available